Payment overview · 2025
General Payments
$952.94
50 reported records · 22 companies
Healthcare provider profile · identity verified
John C Vassallo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOWELL, MI · NPI 1275590119
Verified facts
What the public records show
CMS Open Payments records show John C Vassallo, M.D. received $952.94 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 560 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 560 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1100 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $234.15 | 24.6% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.18 | 9.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.17 | 8.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.72 | 6.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.48 | 5.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.05 | 4.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.52 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.66 | 4.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.60 | 4.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.73 | 3.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.71 | 3.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.29 | 2.8% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.14 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.66 | 2.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.19 | 2.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.95 | 2.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.55 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.17 | 1.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.83 | 1.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.23 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.07 | 1.8% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $15.89 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $932.72 | 49 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $110.57 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.18 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.87 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $73.42 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.52 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.52 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.06 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.05 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.52 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $28.71 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1100 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 192 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 560 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
133 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
192 | 32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
560 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 31 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
157 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
560 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
92 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1100 | 99 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2608 | 292 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1583 | 162 |
| Furosemide | Furosemide | 1216 | 117 |
| Eliquis | Apixaban | 1100 | 99 |
| Lisinopril | Lisinopril | 994 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 961 | 119 |
| Gabapentin | Gabapentin | 944 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 855 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 782 | 75 |
| Metformin Hcl | Metformin Hcl | 744 | 88 |
| Metoprolol Tartrate | Metoprolol Tartrate | 669 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 656 | 41 |
| Losartan Potassium | Losartan Potassium | 612 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 603 | 63 |
| Sertraline Hcl | Sertraline Hcl | 586 | 46 |
| Bumetanide | Bumetanide | 570 | 34 |
| Jardiance | Empagliflozin | 560 | 38 |
| Spironolactone | Spironolactone | 516 | 42 |
| Trazodone Hcl | Trazodone Hcl | 500 | 50 |
| Potassium Chloride | Potassium Chloride | 499 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 480 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 468 | 34 |
| Carvedilol | Carvedilol | 386 | 41 |
| Donepezil Hcl | Donepezil Hcl | 379 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 377 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 350 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 343 | 34 |
| Mirtazapine | Mirtazapine | 336 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 333 | 16 |
| Simvastatin | Simvastatin | 331 | 42 |
| Allopurinol | Allopurinol | 330 | 34 |
| Buspirone Hcl | Buspirone Hcl | 315 | 21 |
| Divalproex Sodium | Divalproex Sodium | 306 | 15 |
| Levetiracetam | Levetiracetam | 301 | 14 |
| Ezetimibe | Ezetimibe | 284 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 276 | 23 |
| Baclofen | Baclofen | 258 | 20 |
| Montelukast Sodium | Montelukast Sodium | 221 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 218 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 211 | 47 |
| Bupropion Xl | Bupropion Hcl | 210 | 17 |
| Olanzapine | Olanzapine | 196 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 47 |
| Farxiga | Dapagliflozin Propanediol | 192 | 32 |
| Januvia | Sitagliptin Phosphate | 187 | 12 |
| Omeprazole | Omeprazole | 178 | 62 |
| Prednisone | Prednisone | 170 | 25 |
| Benztropine Mesylate | Benztropine Mesylate | 166 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 65 |
| Xarelto | Rivaroxaban | 157 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 154 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 154 | 15 |
| Finasteride | Finasteride | 150 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 145 | 12 |
| Celecoxib | Celecoxib | 143 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 143 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 140 | 58 |
| Myrbetriq | Mirabegron | 138 | suppressed |
| Anastrozole | Anastrozole | 135 | suppressed |
| Linzess | Linaclotide | 133 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 132 | 47 |
| Torsemide | Torsemide | 131 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 129 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 34 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 128 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 128 | suppressed |
| Risperidone | Risperidone | 121 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 114 | suppressed |
| Memantine Hcl | Memantine Hcl | 108 | 11 |
| Atenolol | Atenolol | 101 | 22 |
| Methocarbamol | Methocarbamol | 99 | 17 |
| Alprazolam | Alprazolam | 98 | 32 |
| Lovastatin | Lovastatin | 98 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 20 |
| Alendronate Sodium | Alendronate Sodium | 96 | 20 |
| Chlorthalidone | Chlorthalidone | 95 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 17 |
| Trulicity | Dulaglutide | 92 | 13 |
| Latanoprost | Latanoprost | 90 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 87 | 35 |
| Dantrolene Sodium | Dantrolene Sodium | 82 | suppressed |
| Entresto | Sacubitril/Valsartan | 82 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 82 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 81 | suppressed |
| Aripiprazole | Aripiprazole | 80 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 13 |
| Methotrexate | Methotrexate Sodium | 77 | suppressed |
| Calcitriol | Calcitriol | 76 | suppressed |
| Novolog Flexpen | Insulin Aspart | 74 | 20 |
| Digoxin | Digoxin | 73 | suppressed |
| Cephalexin | Cephalexin | 71 | 24 |
| Meloxicam | Meloxicam | 68 | 20 |
| Propranolol Hcl | Propranolol Hcl | 68 | 12 |
| Lorazepam | Lorazepam | 66 | 25 |
| Colchicine | Colchicine | 65 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 65 | suppressed |
| Glipizide Er | Glipizide | 64 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 63 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 59 | suppressed |
| Folic Acid | Folic Acid | 57 | suppressed |
| Glimepiride | Glimepiride | 57 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 56 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 56 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 56 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 15 |
| Labetalol Hcl | Labetalol Hcl | 55 | suppressed |
| Lubiprostone | Lubiprostone | 55 | suppressed |
| Pregabalin | Pregabalin | 55 | 16 |
| Armour Thyroid | Thyroid,pork | 54 | suppressed |
| Glipizide | Glipizide | 54 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 52 | suppressed |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Valsartan | Valsartan | 52 | suppressed |
| Topiramate | Topiramate | 51 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 16 |
| Brilinta | Ticagrelor | 46 | suppressed |
| Primidone | Primidone | 46 | suppressed |
| Tradjenta | Linagliptin | 46 | suppressed |
| Felodipine Er | Felodipine | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 29 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 44 | suppressed |
| Famotidine | Famotidine | 44 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 19 |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 44 | suppressed |
| Np Thyroid | Thyroid,pork | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | suppressed |
| Sulfasalazine | Sulfasalazine | 43 | suppressed |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | 25 |
| Methylprednisolone | Methylprednisolone | 42 | 36 |
| Motegrity | Prucalopride Succinate | 42 | suppressed |
| Valproic Acid | Valproic Acid | 41 | suppressed |
| Amoxicillin | Amoxicillin | 39 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 39 | suppressed |
| Lidocaine | Lidocaine | 38 | suppressed |
| Cilostazol | Cilostazol | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 15 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Oxycontin | Oxycodone Hcl | 34 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 32 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Calcium Acetate | Calcium Acetate | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Enulose | Lactulose | 23 | suppressed |
| Minoxidil | Minoxidil | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 18 |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Hydroxyurea | Hydroxyurea | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 11 |
| Morphine Sulfate | Morphine Sulfate | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | 12 |
| Metolazone | Metolazone | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Epogen | Epoetin Alfa | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 12 |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $952.94 · 50 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FUROSCIX, GEMTESA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, NUZYRA, Nayzilam, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, VOWST, VRAYLAR, Wegovy, XTAMPZA, ZAVZPRET, ZENPEP, ZEPBOUND, ZTLido | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error